Skip to main content

Syndax Pharmaceuticals Inc (SNDX) Insider Trading

In the last 90 days, 1 Syndax Pharmaceuticals Inc (SNDX) insider reported no open-market purchases and 1 sale totaling $113,716. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Oct 29, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Oct 29, 2026Dennis PodlesakDirectorSale8,000$14.21$113,716
Jul 8, 2026Michael A MetzgerChief Executive OfficerSale32,375$24.24$784,776
Jun 12, 2026Nicholas A.J. BotwoodHead of R&D, CMOSale65,515$18.07$1,183,640
Jun 1, 2026Keith A. GoldanChief Financial OfficerSale1,177$18.99$22,351
Jun 1, 2026Michael A MetzgerChief Executive OfficerSale6,847$18.99$130,025

Common questions

SNDX insider trading FAQ

Are SNDX insiders buying or selling?
Over the last 90 days, SNDX insiders were net sellers, reporting $0.00 of open-market purchases and $113,716 of sales.
When was the last SNDX insider purchase?
No open-market insider purchase of Syndax Pharmaceuticals Inc stock was reported in the last 90 days.
Where does SNDX insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Syndax Pharmaceuticals Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.